Maximum quantity allowed is 999
请选择数量
CAS RN: 165800-06-6 | 產品號碼: Z0031
Zoledronic Acid Monohydrate
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | Z0031 |
| 純度/分析方法 | >98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__5H__1__0N__2O__7P__2·H__2O = 290.11 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Refrigerated (0-10°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 165800-06-6 |
| 相關CAS RN | 118072-93-8 |
| Reaxys-RN | 9667036 |
| PubChem Substance ID | 253662255 |
| Merck Index(14) | 10187 |
| MDL編號 | MFCD00867791 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Water | 5.5 to 8.8 % |
| NMR | confirm to structure |
性質
| 熔點 | 245 °C(dec.) |
| Degree of solubility in water | 7 g/l 25 °C |
| 溶解性（不溶於） | Methanol, Ethanol |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H361 : Suspected of damaging fertility or the unborn child. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | SZ8562450 |
運輸資料
| HS編碼* | 2933.29-000 |
Application
Bone Resorption Inhibitor
References
- 1)Bisphosphonates: From bench to bedside
- 2)Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase
- 3)Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
- 4)Role of zoledronic acid in the prevention and treatment of osteoporosis
- 5)Emerging strategies and therapies for treatment of Paget’s disease of bone
- 6)The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy
考研文獻
文章/手冊
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。